Displaying 471 - 480 of 545 results
-
Evaluation of the safe use of opioids national collaborativeThis report presents an evaluation of the Health Quality & Safety Commission-led safe use of opioids national collaborative.
-
ALERT 17: Alteplase or tenecteplase?An alert has been issued to highlight the need to clearly differentiate between stroke thrombolysis and myocardial infarction thrombolysis.
-
Learning from adverse events report 2017–18This is the annual learning from adverse events report for 2017–18, published by the Health Quality & Safety Commission. The report covers adverse events reported by New Zealand's 20 district health boards (DHBs) and other providers.
-
Safe Medication Management newsletters - 2010Newsletters from the SMM programme for the year 2010
-
Safe use of opioids collaborative information for DHB hospitalsInformation document for DHBs about the breakthrough series collaborative on safe use of opioids in hospitals.
-
Safe use of opioids measurement: frequently asked questionsFrequently asked questions about measurement for the safe use of opioids.
-
Opioid implementation packageThis package outlines the next steps and what the options are to make a significant difference in opioid-induced adverse drug events.
-
Acetylcysteine for the treatment of paracetamol overdose and toxicity – 2-bag dosing guidanceNew dosing guidance for acetylcysteine for the treatment of paracetamol overdose and toxicity issued in January 2019.
-
Safety Signal: Changes to the labelling of Bicillin LA®Following international practice, the name and strength description for Bicillin LA® has been changed. The expression of the name will now be benzathine benzylpenicillin tetrahydrate. The expression of product strength will now be 1,200,000 units/2.3
-
#O2TheFix toolkitTools developed by Waitematā DHB to encourage the safer prescribing and the best practice use of oxygen therapy, to reduce harm to patients.